Skip to main navigation
Intercept Pharmaceuticals homepage
  • News
Intercept Pharmaceuticals Logo
Menu
Close✕
  • About Us
    • Leadership
    • News
    • Company Statements
    • OCALIVA: Withdrawal Process
  • Our Focus
    • Meet Ally
    • Patient Resources
  • Our Research
    • FXR
    • Pipeline
    • Medical Information Request Form
  • Careers
    • Job Postings
  • Contact Us
  • Media
Home > Our Research

Science that
REVOLUTIONIZES

Using key discoveries in the field of liver health, we’re innovating and investigating treatment for rare and serious liver diseases, helping solve some of today’s toughest medical challenges and building healthier tomorrows.

  • Our Research
    • FXR
    • Pipeline
    • Medical Information Request Form
    • Medical Information Request Form

Farnesoid X Receptor

Research is shedding light on the complex and powerful connection between bile acid and the farnesoid X receptor (FXR). Understand the metabolic effects of FXR.

Learn more
farnesoid x receptor

Our Pipeline

We are leveraging our decades of research and background in bile acids and FXR agonism to develop effective treatments for people living with chronic liver diseases.

Learn more

Medical Information

If you are a healthcare professional and have a medical inquiry, visit our Medical Information website.

Learn more

  • Our Focus
    • Meet Ally
    • Patient Resources
  • Our Research
    • FXR
    • Pipeline
    • Medical Information Request Form
  • About Us
    • Leadership >
    • News >
  • Careers
    • Job Postings
Intercept Pharmaceuticals Logo
  • Website Privacy Policy
  • Consumer Health Data Privacy Policy
  • EU-US Data Privacy Framework (DPF) Policy
  • Corporate Compliance
  • Terms of Use
  • Contact Us
  • Cookie Preferences
  • Transparency Disclosures
305 Madison Avenue |Morristown, NJ 07960|T: 1-844-782–4278
© 2024 Intercept Pharmaceuticals, Inc.
US-NP-OT-0023
US-NP-OT-0023

YOU ARE NOW leaving interceptpharma.com


You are now leaving Intercept Pharmaceuticals’ corporate website and entering a site intended for U.S. audiences only.

Continue

YOU ARE NOW leaving interceptpharma.com


You are now leaving Intercept Pharmaceuticals’ corporate website. Intercept does not control or endorse the content of this external site.

Continue

YOU ARE NOW leaving interceptpharma.com


You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Intercept provides this link as a service to its website visitors. Intercept is not responsible for the content or the privacy policy of any third party websites.

Close this window to return to Intercept Pharmaceuticals’ site or click ‘Continue’ to proceed.

Continue

United States (US)
European Union (EU)
Canada
Israel
Switzerland
Australia
Liechtenstein
United Arab Emirates (UAE)

Close

Exploring Racial Differences and Disparities in PBC Care

Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., has voluntarily withdrawn OCALIVA® (obeticholic acid) from the market for the treatment of primary biliary cholangitis (PBC), effective November 14.

Patients should talk to their healthcare professionals and may also contact Intercept's patient support services (Interconnect at 1-844-622-4278) through December 31, 2025.

Healthcare professionals can contact Medical Information at medinfo@interceptpharma.com or 1-844-782-4278. Additionally, patients or healthcare professionals may request Full Prescribing Information or the OCALIVA Medication Guide by contacting medinfo@interceptpharma.com.

For all other inquiries please contact: info@interceptpharma.com

Acknowledge